Safety and clinical efficacy of rapidly-generated virus-specific T cells with activity against adv, EBV, CMV, HHV6 and BK virus administered after allogeneic hematopoietic stem cell transplant

Παπαδοπούλου, Αναστασία; Katari, Usha L.; Gerdemann, Ulrike; Tzannou, Ifigeneia; Martinez, Caridad; Leung, Kathryn; Carrum, George; Gee, Adrian P.; Vera, Jennifer; Krance, Robert A.; Brenner, MK; Rooney, Cliona M.; Heslop, H.; Leen, Ann M.

doi:10.1016/j.jcyt.2014.01.014

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the cells produced clinical benefit and complete virological responses in 8 of 10 patients treated for active infections associated with one or more of the targeted viruses. 82 We are currently testing the activity of pepmix-stimulated VSTs directed against EBV, AdV, CMV, human herpesvirus 6 and BK virus (clinicaltrials.gov) 83 (Figure 1). …”

Section: Simplifying Vst Productionmentioning

confidence: 99%

Accelerating immune reconstitution after hematopoietic stem cell transplantation

Tzannou

Leen

2014

Clin & Trans Imm

View full text Add to dashboard Cite

Viral infections remain a significant cause of morbidity and mortality after hematopoietic stem cell transplantation. Pharmacologic agents are effective against some pathogens, but they are costly and can be associated with significant toxicities. Thus, many groups have investigated adoptive T-cell transfer as a means of hastening immune reconstitution and preventing and treating viral infections. This review discusses the immunotherapeutic strategies that have been explored.

show abstract

Section: Simplifying Vst Productionmentioning

confidence: 99%

Accelerating immune reconstitution after hematopoietic stem cell transplantation

Tzannou

Leen

2014

Clin & Trans Imm

View full text Add to dashboard Cite

show abstract

“…A case of VZV‐specific T cells successfully eradicating chronic VZV infection of a liver allograft (albeit with significant T‐cell‐mediated damage to the infected liver) and a case of JC virus‐specific cells to successfully treat progressive multifocal leukoencephalopathy have been reported . Some multipathogen‐specific T cell trials are have shown promising results . We have recently added Aspergillus to our suite of T cell target pathogens and have treated the first two patients on a trial with seven pathogen targets (CMV, EBV, adenovirus, VZV, BKV, influenza and Aspergillus) with no immediate toxicities.…”

Section: Adoptive T Cell Transfer For Immune Reconstitutionmentioning

confidence: 99%

Moving towards pathogen‐specific T cells post‐stem cell transplant as standard of care

Blyth

Clancy

Gottlieb

2015

ISBT Science Series

View full text Add to dashboard Cite

Infection remains a large contributor to mortality post-allogeneic haemopoietic stem cell transplantation (HSCT). Non-bacterial pathogens cause disease post-HSCT due to impaired cellular immunity that persists for months to years. Treatment with antiviral or antifungal pharmacotherapy is problematic due to drug toxicity, treatment failure and high cost. Pathogen-specific T cells (PSTs) from transplant donors provide a potential solution to the problem of impaired recipient immunity by directly and rapidly reconstituting immunity, thereby preventing or controlling infections. A number of phases I and II clinical trials of PSTs that have focused primarily on cytomegalovirus, Epstein-Barr virus and adenovirus have now been performed in the prophylactic, pre-emptive and treatment settings. These trials show that transferred cells are safe and that they expand in vivo, respond to viral antigens and can prevent or control disease. At the current time, manufacture remains the domain of large centres with the necessary expertise and infrastructure, but automation and standardization will allow techniques to be more widely adopted. It is clear that adoptive T cell transfer will form part of the future of transplantation, with the current challenge being to perform large randomized clinical trials demonstrating safety and efficacy to justify the investment in infrastructure required for widespread incorporation of this therapy into routine clinical practice.

show abstract

Safety and clinical efficacy of rapidly-generated virus-specific T cells with activity against adv, EBV, CMV, HHV6 and BK virus administered after allogeneic hematopoietic stem cell transplant

Cited by 2 publications

References 0 publications

Accelerating immune reconstitution after hematopoietic stem cell transplantation

Accelerating immune reconstitution after hematopoietic stem cell transplantation

Moving towards pathogen‐specific T cells post‐stem cell transplant as standard of care

Contact Info

Product

Resources

About